Mangoceuticals, Common Financials

MGRX Stock   2.47  0.34  12.10%   
Based on the analysis of Mangoceuticals, Common's profitability, liquidity, and operating efficiency, Mangoceuticals, Common Stock is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, Mangoceuticals, Common's Total Assets are fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 1.5 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 202.3 K in 2025. Key indicators impacting Mangoceuticals, Common's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.05040.053
Notably Down
Slightly volatile
The financial analysis of Mangoceuticals, Common is a critical element in measuring its lifeblood. Investors should not minimize Mangoceuticals, Common's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(8.27 Million)

  
Please note, the imprecision that can be found in Mangoceuticals, Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mangoceuticals, Common Stock. Check Mangoceuticals, Common's Beneish M Score to see the likelihood of Mangoceuticals, Common's management manipulating its earnings.

Mangoceuticals, Common Stock Summary

Mangoceuticals, Common competes with FOXO Technologies, Healthcare Triangle, Bullfrog, and EUDA Health. Mangoceuticals, Common is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP56270V106 56270V205
LocationTexas; U.S.A
Business Address15110 North Dallas
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.mangoceuticals.com
Phone214 242 9619

Mangoceuticals, Common Key Financial Ratios

Mangoceuticals, Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Mangoceuticals, Common's current stock value. Our valuation model uses many indicators to compare Mangoceuticals, Common value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mangoceuticals, Common competition to find correlations between indicators driving Mangoceuticals, Common's intrinsic value. More Info.
Mangoceuticals, Common Stock is regarded second in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Mangoceuticals, Common's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mangoceuticals, Common's earnings, one of the primary drivers of an investment's value.

Mangoceuticals, Common Systematic Risk

Mangoceuticals, Common's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mangoceuticals, Common volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Mangoceuticals, Common correlated with the market. If Beta is less than 0 Mangoceuticals, Common generally moves in the opposite direction as compared to the market. If Mangoceuticals, Common Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mangoceuticals, Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mangoceuticals, Common is generally in the same direction as the market. If Beta > 1 Mangoceuticals, Common moves generally in the same direction as, but more than the movement of the benchmark.

Mangoceuticals, Common Thematic Clasifications

Mangoceuticals, Common Stock is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
HealthcareView
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Mangoceuticals, Common Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mangoceuticals, Common's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mangoceuticals, Common growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0182

At this time, Mangoceuticals, Common's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Mangoceuticals, Common March 26, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Mangoceuticals, Common help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mangoceuticals, Common Stock. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mangoceuticals, Common Stock based on widely used predictive technical indicators. In general, we focus on analyzing Mangoceuticals, Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mangoceuticals, Common's daily price indicators and compare them against related drivers.

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.